#Japan #Tokyo #gene therapy #Restore Vision #RV-001

Restore Vision's Groundbreaking Interim Results on RV-001

On May 1, 2026, Restore Vision Inc. unveiled initial results from their Phase I/II first-in-human clinical trials of RV-001, an optogenetic gene therapy aimed at treating advanced Retinitis Pigmentosa (RP). This gene therapy, leveraging a chimeric rhodopsin, aims to restore vision by activating the body's native phototransduction pathway, offering new hope to those suffering from this degenerative eye disease—widely recognized as the leading inherited cause of blindness in adults, affecting around two million people globally.

The results were shared during two prominent events at the Eyecelerator at ARVO 2026 and the Retinal Therapeutics Innovation Summit in Denver, Colorado. Clinical findings indicate the absence of dose-limiting toxicities or serious adverse effects in the initial low and high-dose cohorts, with a total of six participants exhibiting promising improvements.

Key Findings from the RV-001 Trial

The ongoing trials assess the safety and initial efficacy of a single intravitreal injection of RV-001 in individuals with no light perception (NLP). Interim results show both cohorts, comprising three patients each, demonstrated remarkable outcomes. Notably, participants in the high-dose cohort, starting at NLP, reported light perception or better within a month following treatment. Furthermore, one participant recorded measurable visual acuity using the Berkeley Rudimentary Vision Test (BRVT).

This treatment's effectiveness was showcased through dose-dependent improvements across multiple endpoints, including visual acuity, mobility tasks, and object recognition—signifying a potential clinical breakthrough in restoring visual function even in completely blind patients. RV-001 is administered via an adeno-associated virus vector, differentiating it from conventional optogenetic therapies, as it does not require external devices or intense lighting for activation.

Yusaku Katada, M.D., CEO of Restore Vision, expressed optimism regarding these preliminary results, emphasizing that they underscore the potential distinct advantages of RV-001 in enhancing visual function in ways that are both meaningful and clinically relevant.

Future Directions

The study's primary focus remains on safety; however, additional exploration of efficacy across broader patient populations is on the horizon. As Restore Vision continues its commitment to pioneering transformative gene therapies, these interim findings mark a significant step forward in developing effective solutions addressing critical unmet medical needs.

??? About Restore Vision
Restore Vision Inc. is at the forefront of developing groundbreaking gene therapies aimed at retinal disorders. By melding academic excellence with entrepreneurial innovation, the company aims to significantly improve patient outcomes and quality of life. The pioneering spirit showcased in RV-001 paves the way for future discoveries that could ultimately revolutionize treatment approaches for vision loss.

In conclusion, as Restore Vision embarks on further research and development efforts, the enthusiasm surrounding RV-001 continues to grow, with eyes turned toward future clinical milestones and the potential transformative power of gene therapy in restoring sight to those who have lost it.